Search

Inflammatory infiltration of synovial M1 macrophages, high levels of ROS, and NO exacerbate osteoarthritis (OA) progression. The PdZn/CoSA‐NC nanozymes, which are highly ordered PdZn intermetallic nanoparticles loaded with Co single atom N‐doped carbon‐rich in multi‐level pores, in an attempt to serve as SOD and CAT mimicking nanozymes for OA therapy is designed. The PdZn/CoSA‐NC nanozymes' high electron transfer and dual active site sufficient exposure enhances free radical adsorption and lower reaction energies, accelerating SOD‐like, CAT‐like, and GPx‐like catalyzed reactions, outperforming CoSA‐NC and PdZn/NC alone. Furthermore, PdZn/CoSA‐NC nanozymes exhibit favorable biocompatibility, reduce synovial macrophage oxidative stress in OA, alleviate hypoxia, restore mitochondrial function, regulate energy metabolism, increase antioxidant factors, and reduce inflammatory factors, thus effectively mitigating the progression of OA. Mechanistically, PdZn/CoSA‐NC nanozymes downregulate M1‐type phenotypic markers like IL‐1β by regulating purine metabolism. The PdZn/CoSA‐NC nanozymes offer a novel approach to treating oxidative stress‐related inflammatory diseases. [ABSTRACT FROM AUTHOR]

Inflammatory osteolysis is often caused by the excessive activation of osteoclasts stimulated by bacterial products such as lipopolysaccharide. The natural flavonoid trifolirhizin (TRI) has anti‐inflammatory properties; however, its function in inflammatory bone lysis remains unclear. This study aimed to elucidate the potential regulatory mechanisms of TRI in osteoclasts.Tartrate‐resistant acid phosphatase (TRAP) staining, acid secretion assays, podosomal actin belt fluorescence staining, and bone resorption assays were used to investigate the effects of TRI on osteoclast differentiation and bone resorption. A reactive oxygen species (ROS) measurement kit was used to detect the effect of TRI on ROS levels in osteoclasts. The effects of TRI on genes and signaling pathways related to osteoclast differentiation were determined by quantitative polymerase chain reaction (qPCR) and western blotting. A mouse model of lipopolysaccharide‐mediated inflammatory osteolysis was established, and the effects of TRI treatment on bone mass were observed using micro‐CT and histological examination. Mechanistically, TRI reduced ROS production by inhibiting receptor activator of nuclear factor‐κB ligand (RANKL)‐induced activation of the nuclear factor‐κB (NF‐κB) and mitogen‐activated protein kinase (MAPK) signaling pathways, and by upregulating the expression levels of the anti‐ROS enzymes heme oxygenase‐1 (HO‐1) and catalase (CAT), which contributed to the degradation of ROS, ultimately leading to a decrease in osteoclastogenesis. TRI inhibited osteoclast formation and ameliorated lipopolysaccharide (LPS)‐mediated inflammatory osteolysis. Thus, TRI may be a candidate agent for anti‐inflammatory osteolysis. [ABSTRACT FROM AUTHOR]

ObjectiveMany publications report outcomes of surgical treatment for neurothoracic outlet syndrome (NTOS); however, high-quality meta-analyses regarding objective evaluation system accessing the long-term outcome of NTOS are lacking. This meta-analysis summarizes and compares the outcomes of Derkosh's classification and vas visual analog scale of the supraclavicular neuroplastic of brachial plexus (SNBP) and trams auxiliary first rib resection (TFRR).MethodsThe Cochrane Library, PubMed, EMBASE, Allied and Complementary Medicine (AMED) were searched for papers published between January 1980 and February 2021, using the keywords “thoracic outlet syndrome,” “treatment, surgical.” Articles were eligible for inclusion if the following criteria were met studies describing outcomes of surgery for NTOS, published in English, human studies, and available in full text. The exclusion criteria were case reports (n < 10), reviews, abstracts, and studies lacking a control group or without evaluation for two types of surgery.ResultsWe included 10 studies with 1,255 cases, out of which 622 were in the SNBP group; and 633 were in the TFRR group. After surgery (≥12 months), Derkash's classification was improved in 425 cases with SNBP and 364 cases with TFRR. OR = 1.34 (95% CI: 0.94, 1.92), P = 0.03; vas visual analog scale was improved in 282 cases in the SNBP group and 214 cases in the TFRR group. OR = 1.08 (95% CI: 0.63, 1.85), P = 0.78.ConclusionThis meta-analysis shows that both SNBP and TFRR are effective for NTOS, but that SNBP is better than TFRR in improving Derkash's classification in the long term. Although patients treated with SNBP are more satisfactory, there is no significant difference in vas visual analog scale from TFRR.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42021254203, PROSPERO CRD42021254203.